Study design issues in evaluating immune biomarkers

Current Opinion in HIV and AIDS

Volumn 8, Issue 2, 2013, Pages 147-154

  Bosch, Ronald J ^a   Zhang, Xinyan ^a   Sandler, Netanya G ^b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

biomarker; clinical trials; measurement error; observational research; surrogate marker

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; VIRUS RNA;

CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE MARKER; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; VIRUS REPLICATION;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; HIV; HIV INFECTIONS; HUMANS; MONITORING, IMMUNOLOGIC; RESEARCH DESIGN;

EID: 84873472980     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835d3259     Document Type: Review

References (65)

1. Biomarker Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: Summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010; 5:480-490.
3. Baker JV, Peng G, Rapkin J, et al. CD4 count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
5. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
6. Hunt P, Rodriguez B, Shive C, et al. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/AIDS. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, W.A.
7. Plaeger SF, Collins BS, Musib R, et al. Immune activation in the pathogenesis of treated chronic HIV disease: A workshop summary. AIDS Res Hum Retroviruses 2012; 28:469-477.
8. Deeks S. Therapeutic approaches to curing HIV infection. AIDS Vaccine 2012; September 9-12 September 2012; Boston MA.\
9. Mildvan D, Landay A, De Gruttola V, et al. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997; 24: 764-774.
10. Mellors JW, Mun? oz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
11. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8 T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4cell count, soluble immune activation markers, or combinations of HLADR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
12. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
13. Keating SM, Golub ET, Nowicki M, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011; 25:1823-1832.
14. Brown TT, Tassiopoulos K, Bosch RJ, et al. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33:2244-2249.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 5 October 2012].
16. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: A recurrent events analysis. J Infect Dis 2012; 205:1230-1238.
17. Kamat A, Misra V, Cassol E, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 2012; 7:e30881.
18. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
19. Capeau J. Premature aging and premature age-related comorbidities in hivinfected patients: facts and hypotheses. Clin Infect Dis 2011; 53: 1127-1129.
20. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-1139.
21. Lifson AR, Belloso WH, Davey RT, et al. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials 2010; 11: 205-219.
22. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-940.
23. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
24. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
25. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
26. Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010; 201:823-834.
27. Zheng L, Taiwo B, Gandhi R, et al. Factors associated with CD8 T cell activation in HIV-1-infected participants who have been on antiretroviral therapy for-96 weeks in ACTG studies. 19th International AIDS Conference; 22-27 July 2012; Washington DC.\
28. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4 T-cell count and numbers of CD28 CD4 T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-2023.
29. Meier A, Fisher A, Sidhu HK, et al. Rapid loss of dendritic cell and monocyte responses to TLR ligands following venipuncture. J Immunol Methods 2008; 339:132-140.
30. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008; 300:506-507.
31. Egger M, Spycher BD, Sidle J, et al. Correcting mortality for loss to follow-up: A nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 2011; 8:e1000390.
32. Robb M. Viral dynamics and immune response in acute infection and their impact on viral set-point. AIDS Vaccine 2012; 9-12
33. Gianella S, Strain MC, Rought SE, et al. Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol 2012; 86:1307-1315.
34. Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. BMJ 1995; 310:170.
35. Rosner B, WillettWC. Interval estimates for correlation coefficients corrected for within-person variation: Implications for study design and hypothesis testing. Am J Epidemiol 1988; 127:377-386.
36. Funderburg N, Andrade A, Chan E, et al. Delayed reduction in CD4 T cell turnover following viral control correlates with markers of microbial translocation in treatment-nai?ve patients receiving RAL-based ART: preliminary results from ACTG A5248. 18th Conference on Retroviruses and Opportunistic Infections; 27 FebruaryY2 March 2011; Boston, MA.\
37. Aziz N, Nishanian P, Mitsuyasu R, et al. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999; 6:89-95.
38. Gordis L. Epidemiology. 3rd ed. Philadephia, PA: Elsevier Saunders; 2004.
39. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Med 2008; 5:e78.
40. Lasky T, Stolley PD. Selection of cases and controls. Epidemiol Rev 1994; 16:6-17.
41. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 73:1-11.
42. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52:1165-1172.
43. Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005; 14:1899-1907.
44. Shive CL, Biancotto A, Funderburg NT, et al. HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr 2012; 61:145-152.
45. Lederman MM, Kalish LA, Asmuth D, et al. 'Modeling' relationships among HIV-1 replication, immune activation and CD4 T-cell losses using adjusted correlative analyses. AIDS 2000; 14:951-958.
46. Ho? fler M. Causal inference based on counterfactuals. BMC Med Res Methodol 2005; 5:28.
47. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-666.
48. Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-6314.
49. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4 T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203:1474-1483.
50. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203:756-764.
51. Pettersen FO, Torheim EA, Dahm AE, et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 2011; 85: 6557-6566.
52. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed. St Louis, MO: Mosby-Year Book; 1996.
53. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2:93-113.
54. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11:167-178.
55. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1998; 8:431-440.
56. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22:485-502.
57. Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004; 1:189-195.
58. Molenberghs G, Burzykowski T, Alonso A, Buyse M. A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 2004; 13:177-206.
59. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005; 24:67-78.
60. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4 lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929-938.
61. Hughes MD, Daniels MJ, Fischl MA, et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: A meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12:1823-1832.
62. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: Antiretroviral drugs using plasma HIV RNA measurements Yclinical considerations for accelerated and traditional approval 2002. http://www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/ucm070968.pdf [Accessed 5 October 2012].
63. Abrams D, Lé vy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-1559.
64. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001; 357:373-380.
65. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: Observational studies. Lancet 2001; 357:455-462.